TAK-625

DRUG2 trials

Sponsors

Takeda

Conditions

Alagille Syndrome (ALGS)Progressive Familial Intrahepatic Cholestasis (PFIC)

Phase 3

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

CompletedNCT05543174

TakedaAlagille Syndrome (ALGS)

Start: 2023-01-16End: 2025-07-25Updated: 2026-01-29

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

CompletedNCT05543187

TakedaProgressive Familial Intrahepatic Cholestasis (PFIC)

Start: 2023-01-10End: 2025-07-22Updated: 2026-01-28